Analysis of resistance to clofazimine in tuberculosis patients
- Author:
- No author available
- Journal Title:
- Chinese Journal of Tuberculosis and Respiratory Diseases
- Issue:
- 3
- DOI:
- 10.3760/cma.j.cn112147-20210108-00021
- Key Word:
- 结核，肺;氯法齐明;耐药率;药敏试验;Tuberculosis, pulmonary;Clofazimine;Drug resistance rate;Drug sensitivity test
Abstract： Objective:To analyze the drug resistance of tuberculosis patients to clofazimine.Methods:Retrospective analysis was conducted on the case data of 1 770 tuberculosis patients in Department of tuberculosis, Beijing Chest Hospital affiliated to Capital Medical University from January 2015 to June 2018, including 1 225 males and 545 females, aged 8-92 (43.2±15.2) years old. Drug sensitivity tests using proportion method (hereinafter referred to as drug susceptibility test) for TB strains anti-tb drug resistance test. Using χ 2 test or Fisher′s exact test. Results:1 770 cases of tuberculosis patients, 1 713 cases of patients with clofazimine sensitive, of 57 patients with drug resistance, and resistant rate was 3.2% (57/1 770), including patients with recurrent clofazimine, significantly higher than the initial percentages of patients [5.8% (38/656), 1.7% (19/1 114), χ2= 22.129, P = 0.000, P<0.01]; The drug resistance rates of poly-resistant, multi-drug resistant and extensively resistant patients to clofazimine were 1.0% (17/1 770), 1.2% (21/1 770) and 1.1% (19/1 770), respectively. Has a history of hospitalization of clofazimine resistance of multidrug-resistant and extensively drug-resistant patients resistant rate 2.4% (14/594), 2.7% (16/594), respectively, higher than 0.6% (7/1 176) with no history of hospitalized patients, 0.3% (3/1 176), the differences were statistically significant (χ2=10.447,22.099, P=0.001,<0.001). Conclusion:Clofazimine has a low resistance rate, which can improve the treatment success rate of patients with drug-resistant tuberculosis and has important value.
- [1]首都医科大学附属北京胸科医院,中国防痨协会临床试验专业分会,《中国防痨杂志》编辑委员会.氯法齐明治疗结核病的临床应用指南[J].2020,(5).
- [2]张叶,李媛媛,徐建,等.吡法齐明抗耐药结核分枝杆菌作用机制的初步研究[J].2019,(11).
- [3]高谦,梅建.传播才是造成我国结核病高耐药率的主要原因[J].2015,(11).
- [4]桂徐蔚,肖和平,胡忠义,等.氯法齐明对不同耐药类型结核分枝杆菌的体外抑菌活性研究[J].2011,(8).
- [5]Yano T,Kassovska Bratinova S,Teh JS,etc.Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species.[J].2011,286(12).
- [6]Almeida, Deepak,Ioerger, Thomas,Tyagi, Sandeep,etc.Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis[J].2016,60(8).
- [7]Maug,A.K.J.,Salim,M.A.H.,Das,P.K.,etc.Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis[J].2010,182(5).
- [8]Zhen Gong,Hui Li,Yuhua Cai,etc.Biology of MarR family transcription factors and implications for targets of antibiotics against tuberculosis[J].2019,234(11).
- [9]Jiang,G.,Xu,S.,Ou,X.,etc.National survey of drug-resistant tuberculosis in China[J].2012,366(23).
- [10]H, Okusu,D, Ma,H, Nikaido.AcrAB efflux pump plays a major role in the antibiotic resistance phenotype of Escherichia coli multiple-antibiotic-resistance (Mar) mutants.[J].1996,178.
- [11].Drug resistance mechanisms and novel drug targets for tuberculosis therapy[J].2017,44(1).
- [12]Kuaban, C.,Noeske, J.,Rieder, H. L.,etc.High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon[J].2015,19(5).
- [13]Shi, Wanliang,Chen, Jiazhen,Zhang, Ying,etc.Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis[J].2015,70(9).
- [14]Radhakrishnan,A.,Kumar,N.,Wright,C.C.,etc.Crystal structure of the transcriptional regulator Rv0678 of Mycobacterium tuberculosis[J].2014,289(23).
- [15]DeKnegt,G.J.,Bruning,O.,TenKate,M.T.,etc.Rifampicin-induced transcriptome response in rifampicin-resistant Mycobacterium tuberculosis[J].2013,93(1).
- [16]贾芳,宋青山,黄海荣.某医院广泛耐药结核病住院患者耐药特点及危险因素分析[J].2019,(3).
- [17]Gan, Mingyu,Gao, Qian,Wu, Jie,etc.Transmission of multidrug-resistant Mycobacterium tuberculosis in Shanghai, China: a retrospective observational study using whole-genome sequencing and epidemiological investigation[J].2017,17(3).
- [18]M C, Cholo,H I, Boshoff,H C, Steel,etc.Effects of clofazimine on potassium uptake by a Trk-deletion mutant of Mycobacterium tuberculosis.[J].2006,57(1).
- [19]Padayatchi, N.,Metcalfe, J. Z.,Gopal, M.,etc.Systematic review of clofazimine for the treatment of drug-resistant tuberculosis[J].2013,17(8).
- [20].In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug -resistant tuberculosis from Beijing, China.[J].2017,(Spec).
- [21]Provvedi R,Lucarelli AP,Milano A,etc.Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system.[J].2009,89(1).
- [22]Yadong,Du,Chao,Qiu,Xiaohong,Chen,etc.Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: a randomized control trial in China.[J].2019.
- [23]Hartkoorn,R.C.,Uplekar,S.,Cole,S.T..Cross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in mycobacterium tuberculosis[J].2014,58(5).
- [24]Villellas, Cristina,Coeck, Nele,Meehan, Conor J.,etc.Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline[J].2017,72(3).
- [25]N Padayatchi,M Gopal,R Naidoo,etc.Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.[J].2014,69(11).
- [26]Xu, Jian,Wang, Bin,Hu, Minghao,etc.Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis[J].2017,61(6).
- [27]Hassane, S.,Koura, K. G.,Gasana, M.,etc.Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries[J].2018,22(1).